Evidence map›Paper›PMID 39753730›Full record

ReviewNPJ precision oncology2025

A review of deep learning for brain tumor analysis in MRI.

Felix J Dorfner, Jay B Patel, Jayashree Kalpathy-Cramer, Elizabeth R Gerstner, Christopher P Bridge

Abstract readReview
In one paragraph

Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. [Application of hybrid attention guided dual-path residual learning in magnetic resonance imaging diagnosis].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Felix J DorfnerAthinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA, 02129, USA.ORCID http://orcid.org/0009-0003-5914-3233
Jay B PatelAthinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA, 02129, USA.
Jayashree Kalpathy-CramerUniversity of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Elizabeth R GerstnerAthinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA, 02129, USA.
Christopher P BridgeAthinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA, 02129, USA. cbridge@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-2242-351X

Funding

Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastasesR01CA244975 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, GERSTNER, ELIZABETH · 2020 to 2024
$3.4M
NCI NIH HHS R01 CA244975Rappaport Foundation (Phyllis & Jerome Lyle Rappaport Foundation) MGH Research ScholarshipU.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA244975
6 · The paper itself

Abstract

Recent progress in deep learning (DL) is producing a new generation of tools across numerous clinical applications. Within the analysis of brain tumors in magnetic resonance imaging, DL finds applications in tumor segmentation, quantification, and classification. It facilitates objective and reproducible measurements crucial for diagnosis, treatment planning, and disease monitoring. Furthermore, it holds the potential to pave the way for personalized medicine through the prediction of tumor type, grade, genetic mutations, and patient survival outcomes. In this review, we explore the transformative potential of DL for brain tumor care and discuss existing applications, limitations, and future directions and opportunities.

Identifiers

PMID39753730
PMCPMC11698745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.